BriefingWire.com, 12/04/2011 -- Immune Response BioPharma Inc. board has approved a 5000 for 1 stock split effective December 15th 2011 and the board has authorized a share increase to 15 million shares.
Both measures were unanimously voted for by IRBP’s board of directors in favor of the resolutions. The authorized share increase will give the company the flexibility it needs in raising sufficient capital to capitalize the company and execute its current and long term goals of developing both REMUNE for AIDS and NeuroVax for MS. These measures are important steps as the company moves towards a successful launch and commercialization of the vaccines in the coming years.
Forward-Looking Statement
Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. IRBP’s proprietary pipeline includes first in class treatments REMUNE for AIDS, NeuroVax for MS and Sepsicillin for Sepsis Shock. The company has a deep pipeline of experimental drugs it plans to develop.
Plans to raise capital is neither an offer nor solicitation for sale of securities. Forward looking statements are based upon future projections, timeframes and current information and IRBP makes no guarantee that its products will be successful or approved in a highly regulated market. Clinical trials and data may not be sufficient to satisfy regulatory requirements. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
